Targeting Oncogenic Fusion Proteins in Hematologic Malignancies with RNAi
Oncogenic fusion proteins, resulting from chromosomal translocations, are hallmark drivers of many hematologic malignancies. These fusion proteins often function as aberrant transcription factors or kinases, promoting uncontrolled cell growth and survival. Targeting them is a promising therapeutic strategy. RNA interference (RNAi) techniques, including siRNA and shRNA, enable selective silencing of fusion gene transcripts by designing…
